A Therapeutic Equivalence Study of Ketoconazole Cream 2%

Douglas Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Tinea Pedis

Treatments: Drug: Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.); Drug: Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.); Drug: Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04203342

71864602

Details and patient eligibility

About

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.

Full description

A randomized, double-blind, vehicle-controlled, parallel-design, multiple-site study to evaluate the clinical (therapeutic) effet of a generic Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) compared with the reference standard Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc) in subjects with a microbiologically-confirmed, clinical diagnosis of tinea pedis. Approximately 675 subjects, male or female, 18 years or older, will be enrolled.

Enrollment: 682 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Healthy male or non-pregnant, non-lactating female, 18 years of age or older
• Signed ICF meeting all criteria of current FDA regulations
• Female subject of childbearing potential must NOT be pregnant or lactating at Visit 1 (negative urine pregnancy test)
• Female subject of childbearing potential must agree to use of reliable method of contraception.
• Clinical diagnosis of tinea pedis predominantly in interdigital spaces
• Tinea pedis confirmed at baseline by positive KOH wet mount.
• Sum of clinical signs and symptoms score of target lesion at least 4; in addition target lesion must have a minimum score of at least 2 for erythema and a minimum score of at least 2 for either pruritis or scaling.

Exclusion criteria

• Females who are pregnant, lactating or planning to become pregnant during the study period.
• history of, or current psoriasis, lichen planus, or contact dermatitis involving the feet within the previous 12 months.
• history of dermatophyte infections with a lack of response to antifungal systemic or topical therapy (recurrent tinea pedis [i.e.more than 3 infections in the past 12 months] that were unresponsive to previous antifungal therapy).
• history of allergy, hypersensitivity, or intolerance to ketoconazole, other imidazoles, sulfites or any other component of the study product.
• confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.
• current uncontrolled diabetes.
• presence of any other infection of the foot or other disease process that, in the Investigator's opinion, may interfere with the evaluation of the subject's tinea pedis.
• known history of or current impaired wound healing, presence of peripheral vascular disease and/or trophic changes of the lower limbs to an extent that, in the opinion of the Investigator would make the subject unsuitable for the study or compromise subject's safety.
• Signficant history or current evidence of chronic infectious disease, system disorder, organ disorder, immunosuppression (due to disease or therapy, including history of organ transplant), or other medical condition that, in the opinion of the Investigator, would place the subject at undue risk by participating or compromise the integrity of the study data.
• Use of antipruritics, including antihistamines, within 72 hours prior to Visit 1.
• Use of topical corticosteroids, topical antibiotics or topical antifungal therapy (e.g. clotrimazole, econazole, fluconazole) within 2 weeks before Visit 1.
• Use of systemic (e.g. oral or injectable) antibiotics, systemic antifungal therapy, or systemic corticosteroids within 30 days before Visit 1. The use of intranasal, inhaled or ophthalmic corticosteroids for acute or chronic conditions (e.g. allergic conjunctivitis, asthma/COPD maintenance) is acceptable to the extent that, in the opinion of the Investigator, does not compromise safety of subject or integrity of the data.
• Use of oral terbinafine or itraconazole within 2 months before Visit 1.
• Use of immunosuppressive medication or radiation therapy within 3 months before Visit 1.
• Receipt of any drug as part of a research study within 30 days before Visit 1.
• Previous participation in this study.
• Employee of the Investigator or research centre or their immediate family members.
• Inability to understand the requirements of the study and the relative information or are unable or unwilling to comply with the study protocol.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

682 participants in 3 patient groups, including a placebo group

Ketoconazole 2% cream (Douglas Pharmaceuticals America Ltd.)

Experimental group

Description:

Subject will be randomized to either test product/active comparator/placebo comparator. Test product is Ketoconazole 2% cream manufactured by Douglas Pharmaceuticals America Ltd.

Treatment:

Drug: Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)

Ketoconazole 2% cream (Teva Pharmaceuticals USA)

Active Comparator group

Description:

Subject will be randomized to either test product/active comparator/placebo comparator. Active comparator is Ketaconazole 2% cream manufactured by Teva Pharmaceuticals USA.

Treatment:

Drug: Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)

Placebo (Douglas Pharmaceuticals America Ltd.)

Placebo Comparator group

Description:

Subject will be randomized to either test product/active comparator/placebo comparator. Placebo comparator is manufactured by Douglas Pharmaceuticals America Ltd.

Treatment:

Drug: Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)